Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03317613
Other study ID # 2017-0304
Secondary ID 2017-002476-11
Status Completed
Phase Phase 2
First received
Last updated
Start date November 9, 2017
Est. completion date December 20, 2021

Study information

Verified date February 2022
Source Centre Hospitalier Universitaire de Saint Etienne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the oncology area, neuropathic pains are relatively frequent and can be induced by surgery, radiotherapy, or chemotherapy. In usual practice, some units are using qutenza in order to reduce neuropathic pain even though using of this patch for a population of cancer patients has never been demonstrated so far in a prospective study. The present prospective study proposes to evaluate the qutenza efficacy in peripheric neuropathic pain in cancer patients.


Description:

Drugs for neuropathic pains are generally represented by antidepressants, anti-epileptics, opioids, lidocaine patch. However, these drugs can frequently be insufficient, and/or can lead to side effects. Qutenza (8% capsaicin patch) presents an interesting alternative. Qutenza efficacy has been shown in five principal studies conducted on 1988 adults affected by moderate or severe neuropathic pains. All patients presented Postherpetic neuralgia, or HIV associated therapy, or painful diabetic peripheric neuropathies. These studies led to qutenza approbation in Europe and in States in 2009. In oncology, neuropathic pains are relatively frequent and can be induced by the three big actors of the anti-cancerous therapeutic arsenal (surgery, radiotherapy, chemotherapy). In usual practice, some units are usually using qutenza, but the use of this patch for this kind of patients has not been shown in a prospective study. Advantages of this treatment are numerous, and results presented in other therapeutic area are encouraging its use in oncology. The present prospective study proposes to evaluate the qutenza efficacy in peripheric neuropathic pain in cancer patients.


Recruitment information / eligibility

Status Completed
Enrollment 84
Est. completion date December 20, 2021
Est. primary completion date December 4, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient with at least 18 years old; - Patient presenting neuropathic pain secondary to an anti-cancerous treatment; - Patient presenting a DN4 (Neuropathic Pain in Four Questions) score superior or equal to 4 out of 10 - Patient presenting a skin without lesion at the painful area - Informed consent form signed; - Patient affiliated to a social security scheme. Exclusion Criteria: - Hypersensitivity known to capsaicin; - Instable or uncontrolled hypertension; - Painful area localised next to eyes; - Pregnant or breastfeeding woman; - Protected people.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Qutenza
Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.

Locations

Country Name City State
France Centre Jean Perrin Clermont-Ferrand
France Centre Hospitalier Emile Roux Le Puy-en-Velay
France Institut de Cancérologie Lucien Neuwirth Saint-Priest-en-Jarez

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Saint Etienne Institut de Cancérologie de la Loire

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of responders to capsaicin Percentage of responders to capsaicin at one month after the first patch application will be calculated with a relief scale completed by patients. One month
Secondary Maximum value of relief Maximum value of relief will be calculated for patients with relief scale completed by patients at three months after the patch application. Three months
Secondary Correlation coefficient between the relief score and time before first relief Correlation coefficient between maximal value of relief and time between the beginning of painful signs and first patch application. Three months
Secondary Neuropathic pain intensity reported on visual analog scale Minimal, average, and maximal values of neuropathic pain reported on visual analog scale will be evaluated. One year
Secondary Number of toxicities reported Capsaicin patch induced toxicities will be reported, and quoted according to CTCAE version 4.4. One year
Secondary Number of days of response Number of days of response reported by patients where patch are efficient will be reported One year
Secondary Number of days of response to qutenza Number of days between the patch set and the apparition of the first effect on patients will be reported. One year
Secondary Size of painful zones Size of painful zones will be reported. One year
Secondary Number of prescribed antalgics Number of prescribed antalgics will be reported for each patient. One year
Secondary Percentage of patients with a reported chemotherapy Percentage of patients with an obligation to report their chemotherapy because of the pain will be calculated. One year
Secondary Percentage of patients who have received at least 75% of the chemotherapy prescribed Percentage of patients who have received at least 75% of the chemotherapy prescribed will be reported. One year
See also
  Status Clinical Trial Phase
Recruiting NCT04699734 - Peripheral Nerve Block in Patients With Painful Diabetic Polyneuropathy N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Completed NCT05235191 - Effectiveness and Safety of Methadone Versus Placebo for the Control of Neuropathic Pain in Different Etiologies Phase 3
Completed NCT05845177 - Persistent Pain After Hip Replacement
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Not yet recruiting NCT05949554 - Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
Withdrawn NCT05052645 - Ear Acupuncture for Neuropathic Pain N/A
Completed NCT02824588 - Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain N/A
Completed NCT02930551 - Neuromas as the Cause of Pain N/A
Completed NCT02866396 - Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement
Active, not recruiting NCT02560545 - Cannabinoids Effects on the Pain Modulation System N/A
Enrolling by invitation NCT02485795 - Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management N/A
Not yet recruiting NCT02246517 - The Effect of N2O on Chronic Neuropathic Pain Patients Phase 0
Completed NCT02099890 - The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury Phase 3
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Completed NCT01718821 - Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients N/A
Completed NCT01884662 - Virtual Walking for Neuropathic Pain in Spinal Cord Injury N/A
Completed NCT01669967 - The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin N/A
Completed NCT01201317 - A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy Phase 2
Completed NCT01207596 - Evaluating the Efficacy and Safety of Extended Release Hydromorphone (Exalgo) in Patients With Neuropathic Pain Phase 4